Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031538 · ClinicalTrials.gov registry record
Genetic Analysis of Brain Tumors
A clinical trial, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- 674
- Enrollment target
NCT00031538: Clinical Trial study, sponsored by National Cancer Institute (NCI).
NCT00031538 is a clinical trial that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 674 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031538 was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- 674 participants
- Enrollment target
Study Summary
This study will analyze tissue and blood samples from patients with gliomas (a type of brain tumor) to develop a new classification system for these tumors. Tumor classification can help guide treatment, in part by predicting how aggressive a tumor may be. Gliomas are currently classified according to their grade (how quickly they may grow) and the type of cells they are composed of. This system, however, is not always accurate, and sometimes two tumors that appear to be identical under the microscope will have very different growth patterns and responses to treatment. The new classification system is based on tumor genes and proteins, and may be used in the future to better predict a given tumor s behavior and response to therapy. Patients with evidence of a primary brain tumor and patients with a known glioma who will be undergoing surgery to remove the tumor may participate in this study. A sample of tumor tissue removed in the course of a participant s normal clinical care will be used in this study for laboratory analysis of genes and chromosome abnormalities. A small blood sample will also be collected for genetic analysis. In addition, clinical information on patients condition and response to treatment will be collected every 6 months over several years. This information will include findings from physical and neurologic examinations, radiographic findings, and response to therapy, including surgery, radiation and chemotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 674 participants |
| Start Date | 2002-03-01 |
| Est. Completion | 2015-04-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031538
The ClinicalTrials.gov registry entry for NCT00031538 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 674 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00031538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031538 about?
NCT00031538 is a clinical study titled "Genetic Analysis of Brain Tumors". This study will analyze tissue and blood samples from patients with gliomas (a type of brain tumor) to develop a new classification system for these tumors. Tumor classification can help guide treatment, in part by predicting how aggressive a tumor may be. Gliomas are currently classified according ...
What is the current status of trial NCT00031538?
This trial is currently terminated. The enrollment target is 674 participants. The study started on 2002-03-01. Estimated completion is 2015-04-29.
Who is sponsoring clinical trial NCT00031538?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.